Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Amylin enters CNS field through JV with PsychoGenics

Executive Summary

PsychoGenics (CNS drug target validation and compound selection) and metabolic disease company Amylin Pharmaceuticals have created the 50-50 joint venture Psylin Neurosciences and equally participated in the start-up's Series A round.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Drug Discovery Tools
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Joint Venture
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register